PremiumThe FlyPTC Therapeutics price target raised to $60 from $58 at RBC Capital PTC Therapeutics: Promising Pipeline and Strategic Preparations Justify Buy Rating RBC Capital views FDA flexibility on another HD drug as positive for PTC’s ‘518 PremiumThe FlyPTC Therapeutics price target lowered to $42 from $56 at Barclays PTC Therapeutics’ Earnings Call: Strong Start to 2025 Biotech Alert: Searches spiking for these stocks today PremiumThe FlyPTC Therapeutics upgraded to Neutral from Sell at Citi PTC Therapeutics Reports Strong Q1 2025 Results PTC Therapeutics: Balancing Strategic Success with Regulatory Uncertainty – A Hold Rating Analysis 
